2025 HCPCS code J9034
Injection, bendamustine HCL (bendeka), 1 mg
Modifier JW may be applicable if a partial vial is discarded.
The recommended dose of bendamustine HCl for CLL is 100 mg/m2 administered by intravenous infusion over 30 minutes on days 1 and 2 of a 28-day cycle for up to 6 cycles. For indolent B-cell non-Hodgkin lymphoma, the recommended dose is 120 mg/m2 administered by intravenous infusion over 60 minutes on days 1 and 2 of a 21-day cycle for up to 8 cycles. Doses may be modified for toxicity. Bendeka is supplied as 100 mg/4mL (25 mg/mL) as a ready-to-dilute solution in a multidose vial.
In simple words: This code represents 1 milligram of Bendeka, a chemotherapy drug used to treat certain blood cancers like chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma. It works by killing cancer cells or slowing their growth.
One unit of this code represents 1 mg of bendamustine HCl (Bendeka™), an alkylating agent or chemotherapy drug used to treat certain types of cancers such as chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma. It kills cancer cells or slows their growth.
Example 1: A patient with CLL receives 100 mg/m2 of Bendeka on days 1 and 2 of a 28-day cycle., A patient with B-cell non-Hodgkin lymphoma receives 120 mg/m2 of Bendeka on days 1 and 2 of a 21-day cycle., A patient receives a modified dose of Bendeka due to experiencing hematologic or non-hematologic toxicity.
Documentation should include the diagnosis, drug name (Bendeka), dosage administered, route of administration (intravenous infusion), and the date and time of administration.
** J codes include non-self-administered drugs, chemotherapy drugs, immunosuppressive drugs, and inhalation solutions.